iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: http://pubmed.ncbi.nlm.nih.gov/31154307/
Feasibility, acceptability and preliminary outcomes of a mindfulness-based relapse prevention program in a naturalistic setting among treatment-seeking patients with alcohol use disorder: a prospective observational study - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2019 Jun 1;9(5):e026839.
doi: 10.1136/bmjopen-2018-026839.

Feasibility, acceptability and preliminary outcomes of a mindfulness-based relapse prevention program in a naturalistic setting among treatment-seeking patients with alcohol use disorder: a prospective observational study

Cora von Hammerstein  1   2 , Yasser Khazaal  3 , Mathilde Dupuis  2 , Henri-Jean Aubin  1 , Amine Benyamina  1 , Amandine Luquiens  1   4 , Lucia Romo  2   5
Affiliations
Observational Study

Feasibility, acceptability and preliminary outcomes of a mindfulness-based relapse prevention program in a naturalistic setting among treatment-seeking patients with alcohol use disorder: a prospective observational study

Cora von Hammerstein et al. BMJ Open. .

Abstract

Objectives: Cultural differences between the USA and France led us to examine the feasibility, acceptability and preliminary efficacy data on craving, quality of life and psychological flexibility of the add-on Mindfulness-Based Relapse Prevention (MBRP) programme in alcohol use disorder (AUD) in France.

Design: We conducted a prospective observational study with a 6-month follow-up.

Setting: The study was performed in a naturalistic setting with adult outpatients from an addiction department.

Participants: We included all patients with a current AUD who participated in the MBRP programme (n=52). There was no non-inclusion criterion.

Interventions: The intervention was an 8-week MBRP programme, combining elements of traditional relapse prevention cognitive behavioural therapy and mindfulness meditation training. This was an eight-session closed-group programme.

Primary and secondary outcome measures: Primary outcomes were the number of attended treatment sessions, home practice frequency and dropout rate. Secondary outcomes were changes in craving, quality of life, psychological flexibility, drinking outcomes, depression, anxiety and mindfulness levels.

Results: The average number of completed sessions was 6.6 (SD: 1.9). Most participants introduced mindfulness meditation into their everyday lives: 69% and 49% of included patients maintained formal practice at 3 and 6 months, respectively, and 80% and 64% maintained informal practice at 3 and 6 months, respectively. Most participants used mindfulness techniques to face high-risk situations (56% at 6 months). Participants reported a significant reduction in craving, days of alcohol use, depression and anxiety and an increase in mindfulness and psychological flexibility at 6 months.

Conclusions: The MBRP programme showed good acceptability and feasibility. MBRP seemed to improve craving, mindfulness and psychological flexibility. Comparative studies are needed to evaluate the programme's efficacy in AUD.

Trial registration number: 2200863 v 0.

Keywords: MBRP; alcohol use disorder acceptability; craving; mindfulness; relapse prevention.

PubMed Disclaimer

Conflict of interest statement

Competing interests: H-JA has received sponsorship to attend scientific meetings, speaker honoraria and consultancy fees from Bioprojet, D&A Pharma, Ethypharm, Lundbeck, Merck-Serono, Mundipharma, Novartis and Pfizer. LR has received sponsorship to participate in scientific reaserch funded by PMU and FDJ through a convention with the University Paris Ouest Nanterre la Défense. AB has received sponsorship to attend scientific meetings, speaker honoraria and consultancy fees from Bristol-Myers-Squibb, Lundbeck, Merck-Serono and Mylan and is member of the invidor board. AL has received sponsorship to attend scientific meetings, speaker honoraria and consultancy fees from Lundbeck and Indivior.

Figures

Figure 1
Figure 1
Flowchart
Figure 2
Figure 2
Evolution of craving frequency subscales. CEQ-F, Craving Experience Questionnaire (frequency over the last week).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Rehm J, Mathers C, Popova S, et al. . Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet 2009;373:2223–33. 10.1016/S0140-6736(09)60746-7 - DOI - PubMed
    1. Whiteford HA, Degenhardt L, Rehm J, et al. . Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet 2013;382:1575–86. 10.1016/S0140-6736(13)61611-6 - DOI - PubMed
    1. McLellan AT, Lewis DC, O’Brien CP, et al. . Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA 2000;284:1689–95. - PubMed
    1. Magill M, Ray LA. Cognitive-behavioral treatment with adult alcohol and illicit drug users: a meta-analysis of randomized controlled trials. J Stud Alcohol Drugs 2009;70:516–27. 10.15288/jsad.2009.70.516 - DOI - PMC - PubMed
    1. Zywiak WH, Connors GJ, Maisto SA, et al. . Relapse research and the Reasons for Drinking Questionnaire: a factor analysis of Marlatt’s relapse taxonomy. Addiction 1996;91(s12):S121–30. 10.1111/j.1360-0443.1996.tb02332.x - DOI - PubMed

Publication types